NCT07003269Completed
Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT
An Observational Study on the Promotion of Platelet Recovery by Hetrombopag During Haploidentical Hematopoietic Stem Cell Transplantation
Source: ClinicalTrials.gov · Last updated 28 Jul 2026
Brief summary (registry, in English)
The objective of this observational study is to investigate the long-term effects of Hetrombopag in promoting platelet engraftment during haploidentical hematopoietic stem cell transplantation (HSCT) in children with thalassemia, with a specific focus on a 28-day time window post-transplantation. The core question to be addressed is: Is Hetrombopag safe and effective for platelet engraftment in children with thalassemia undergoing haploidentical HSCT within a 28-day post-transplant period? Subjects who received Hetrombopag as part of routine care for haploidentical HSCT in children with thalassemia will be required to complete a 28-day online survey on platelet engraftment outcomes.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 30 (actual)
- First submitted
- 15 May 2025
- Start date
- Sept 2024
- Primary completion date
- Apr 2026
- Lead sponsor
- Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
- Diseases
- Thalassaemia
- NCT number
- NCT07003269
What you commit to
- Study type: Observational
- Participants enrolled: 30
- From Sept 2024 to the primary completion date, Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of a fully matched donor with refusal of haploidentical transplantation.
- Donor-specific antibodies (DSA) \>5,000 and unable to decrease below 3,000 after antibody therapy.
- Presence of transplant contraindications as assessed by the transplant team.
Other illness
- Positive hepatitis B DNA test result.
- Active infection at the time of enrollment.
Lab values
- Donor or recipient with transaminase levels \>2× the upper limit of normal (ULN).
Who the study is looking for
- Diagnosed with severe thalassemia via thalassemia gene testing, transfusion history, and complete blood count (CBC).
- Pediatric patients aged 2-17 years.
- Consented to haploidentical transplantation and evaluated by the transplant team as having no transplant contraindications.
Age in the registry: 2 years to 17 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Haikou Affiliated Hospital of Central South University Xiangya School of Medicine Coordinator of this site? Confirm its status | Haikou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.